Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment
Jiangyue Liu, Iveta Fajnorovà, Yuwei Ren, Kofi Poku, S M Yang, Yu-Hsuan Fu, Cari A. Young, Lupita Lopez, Reginaldo Rosa, Handan Hong, Jingting Hao, Deyi Chen, Pauline Jeanjean, Ines Camille Azrour, Ava Fakharpour, , Saul J. Priceman
Combining 177Lu-PSMA-617 radioligand therapy with PSCA-CAR T cells improves tumor control and survival in prostate cancer models by overcoming antigen heterogeneity and reshaping the immunosuppressive tumor microenvironment.
bioRxiv · Jul 3, 2026 · PreprintCancer Biology